Stock Detail
CYPRESS BIOSCIENCE INC
CYPB @ Yahoo Finance | CYPB Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $6.50 | $6.50 | $0.00 | 0.00% | 0.00 | $6.50 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.00 | $0.00 | 0 | 250.82M | 398,003 | -4.58 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 10.83 | 8.66 | 4.33 | 2.16 | -2.17 |
Stock Profile
Cypress Bioscience, Inc., a biotechnology company, develops products for the treatment of Functional Somatic Syndromes, such as Fibromyalgia Syndrome (FMS), as well as other related chronic pain and central nervous system disorders. It develops Milnacipran, a norepinephrine serotonin reuptake inhibitors agent for the treatment of FMS. As of March 31, 2005, Milnacipran was in a Phase III trial for the treatment of FMS. Milnacipran is a compound, which exerts its effect by inhibiting the reuptake of both norepinephrine and serotonin, two neurotransmitters in regulating pain and mood. The company has a collaboration agreement with Forest Laboratories, Inc.; and a reformulation and new product agreement with Collegium Pharmaceutical, Inc. Cypress Bioscience is based in San Diego, California.